Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 4:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 74 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Celecoxib 400 mg Clear all
Completed Phase 2 Interventional

Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis

NCT00355576
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Celecoxib, Creatine, Minocycline
Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 85 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
19
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2011 · Synced Sep 13, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Results available

Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers

NCT00503035
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Celecoxib, Colonoscopy Biopsy
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Sep 13, 2026, 4:20 PM EDT
Terminated Phase 2 Interventional Results available

Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer

NCT00520845
View directory record Official record
Conditions
Lung Cancer
Interventions
celecoxib, Docetaxel, pemetrexed disodium, laboratory biomarker analysis
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Sep 13, 2026, 4:20 PM EDT
Completed Phase 3 Interventional Results available

Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma

NCT03710876
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
rAd-IFN, Celecoxib Oral Product, Gemcitabine
Biological · Drug
Lead sponsor
Ferring Ventures Limited
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 13, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Results available

Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme

NCT00112502
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Glioblastoma Multiforme
Interventions
Celecoxib, Isotretinoin, Temozolomide, Thalidomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
12
States / cities
Fort Smith, Arkansas • Orlando, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2021 · Synced Sep 13, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Results available

Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis

NCT00571701
View directory record Official record
Conditions
Recurrent Respiratory Papillomatosis
Interventions
celebrex (celecoxib), placebo
Drug
Lead sponsor
Northwell Health
Other
Eligibility
2 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 13, 2026, 4:20 PM EDT
Terminated Phase 1 Interventional Results available

Novel PET Radioligand as an Inflammatory Biomarker in Musculoskeletal Conditions

NCT03912428
View directory record Official record
Conditions
Myositis, Inflammatory, Rheumatoid Arthritis, Healthy Volunteers
Interventions
11C-MC1, Celecoxib, [11C]ER176, Positron Emission Tomography (PET)/computed tomography (CT) Scan
Drug · Diagnostic Test
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 99 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 13, 2026, 4:20 PM EDT
Terminated Phase 2 Interventional

Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer

NCT00045591
View directory record Official record
Conditions
Breast Cancer
Interventions
Celecoxib
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
74
States / cities
Anniston, Alabama • La Jolla, California • Los Angeles, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 13, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Results available

Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery

NCT00466505
View directory record Official record
Conditions
Colorectal Cancer
Interventions
cetuximab, celecoxib, proteomic profiling, immunohistochemistry staining method, laboratory biomarker analysis, mass spectrometry
Biological · Drug · Genetic + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Sep 13, 2026, 4:20 PM EDT
Terminated Phase 2 Interventional

Pre-Prostatectomy Celecoxib or Placebo

NCT02840162
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Prostate Cancer
Interventions
Celecoxib, Placebo
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Sep 13, 2026, 4:20 PM EDT
Completed Phase 1 Interventional

ATRA, Celecoxib, and Itraconazole as Maintenance

NCT02401295
View directory record Official record
Conditions
Relapsed Multiple Myeloma
Interventions
ATRA, Celecoxib, Itraconazole
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 13, 2026, 4:20 PM EDT
Completed Phase 4 Interventional

Efficacy of Lumiracoxib in Relieving Moderate to Severe Post-dental Surgery Pain, Compared to Both Placebo and Celecoxib

NCT00348491
View directory record Official record
Conditions
Pain
Interventions
Lumiracoxib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
17 Years and older
Enrollment
364 participants
Timeline
Started 2006
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 13, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Indomethacin Capsules to Treat Dental Pain

NCT00964431
View directory record Official record
Conditions
Dental Pain
Interventions
Celecoxib 400 mg, Placebo, Indomethacin Test (lower dose), Indomethacin Test (upper dose)
Drug
Lead sponsor
Iroko Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Sep 13, 2026, 4:20 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Celecoxib and Radiation Therapy in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer

NCT00046839
View directory record Official record
Conditions
Lung Cancer
Interventions
celecoxib, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
44
States / cities
Colorado Springs, Colorado • Gainesville, Florida • Jacksonville, Florida + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Sep 13, 2026, 4:20 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum

NCT02054104
View directory record Official record
Conditions
Thoracic Sarcomas, Thorasic Cancers, Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura, Sarcoma, Melanoma
Interventions
H1299 cell lysates, Cyclophosphamide, Celecoxib, Iscomatrix adjuvant
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Sep 13, 2026, 4:20 PM EDT
Withdrawn Phase 4 Interventional

Celecoxib (Celebrex) in the Management of Acute Renal Colic

NCT00304317
View directory record Official record
Conditions
Ureteral Calculi
Interventions
celecoxib, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Sep 13, 2026, 4:20 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Multiple-dose Study of LY3031207 in Healthy Participants

NCT01632566
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo, LY3031207, Celecoxib, Simvastatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Sep 13, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of LY3023703 Testing Pain Relief After Wisdom Teeth Removal

NCT01872910
View directory record Official record
Conditions
Acute Pain
Interventions
Placebo, LY3023703, Celecoxib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2019 · Synced Sep 13, 2026, 4:20 PM EDT
Completed Phase 1 Interventional

Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2

NCT00400374
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Erlotinib, Celecoxib
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Sep 13, 2026, 4:20 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Celecoxib as a Chemopreventive Agent in Current and Former Smokers

NCT00981201
View directory record Official record
Conditions
Smoking, Prevention
Interventions
Celecoxib, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 74 Years
Enrollment
219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Sep 13, 2026, 4:20 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer

NCT01545141
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
Interventions
Chemokin Modulatory Regimen (5 MU/m2), Chemokin Modulatory Regimen (10 MU/m2), Chemokin Modulatory Regimen (20 MU/m2)
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Sep 13, 2026, 4:20 PM EDT
Terminated Phase 1 Interventional

Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas

NCT01143545
View directory record Official record
Conditions
Lung Cancer, Esophageal Cancer, Malignant Pleural Mesothelioma, Sarcoma, Thymic Carcinoma
Interventions
Allogeneic Tumor Cell Vaccine (K562), Celecoxib, cyclophosphamide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Sep 13, 2026, 4:20 PM EDT
Terminated Phase 1 Interventional

Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas

NCT01258868
View directory record Official record
Conditions
Mesolthelioma, Esophageal Cancer, Lung Cancer, Thoracic Sarcomas, Thymoma
Interventions
Celebrex, Tumor cell vaccine
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Sep 13, 2026, 4:20 PM EDT
Withdrawn Phase 3 Interventional

Multimodal Analgesia in Shoulder Arthroplasty

NCT03586934
View directory record Official record
Conditions
Shoulder Pain, Opioid Use
Interventions
Acetaminophen, Celecoxib 200mg, Celecoxib 400 mg, Ropivacaine, Ketorolac, Acetaminophen Injectable Product, Oxycodone, Tramadol, Morphine Injectable Solution, hydrocodone bitartrate and acetaminophen, Morphine, Oxycodone Hydrochloride, Meloxicam
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Sep 13, 2026, 4:20 PM EDT